Brought to you by 
Algeta raises NOK260mm through private placement
17 Feb 2012
Executive Summary
Radiopharmaceuticals developer Algeta ASA netted NOK260mm ($44.9mm) through the private placement of 2mm shares at NOK143 each (a 6% discount) to undisclosed investors. Existing shareholders also sold 1mm shares. Algeta will use some of the proceeds to launch its lead candidate Alpharadin (radium-223 chloride) in the US for cancer patients with bone metastases. Bayer has global marketing rights under a 2009 deal.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Algeta raises NOK260mm through private placement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice